Cytek Biosciences, INC Form 4 insider transactions
NASDAQ
William D. McCombe, CFO of Cytek Biosciences, received stock options and restricted stock units on May 13, 2024, according to a Form 4 filing.
NASDAQ
Cytek Biosciences' Chief Technology Officer, Yan Ming, sold 20,000 shares of common stock at an average price of $5.87 on April 19, 2024, according to a Form 4 filing.
NASDAQ
Ming Yan, Chief Technology Officer of Cytek Biosciences, sold 1,900 shares of common stock on April 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Philippe Busque, SVP at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Cytek Biosciences' Chief Technology Officer, Ming Yan, sold a total of 40,000 shares of common stock on March 18 and 19, 2024, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Chief Operating Officer Paul Christopher Williams of Cytek Biosciences, Inc. reports the vesting and subsequent sale of shares to cover tax obligations.
NASDAQ
Allen Poirson, SVP of Business and Corporate Development at Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Wenbin Jiang, CEO of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Cytek Biosciences CFO Patrik Jeanmonod reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the vesting of restricted stock units and subsequent tax withholding.
NASDAQ
Cytek Biosciences' Chief Technology Officer, Yan Ming, reports the acquisition of stock options and restricted stock units.
NASDAQ
Paul Christopher Williams, COO of Cytek Biosciences, was granted stock options and restricted stock units (RSUs) on March 6, 2024, according to a Form 4 filing with the SEC.
NASDAQ
Form 4: Cytek Biosciences Executive Poirson Allen Reports Stock Option and Restricted Stock Unit Awards
Cytek Biosciences' SVP, Poirson Allen, reports the acquisition of stock options and restricted stock units, signaling continued alignment with the company's long-term performance.
NASDAQ
Wenbin Jiang, CEO of Cytek Biosciences, reports the acquisition of stock options and restricted stock units.
NASDAQ
Philippe Busque, SVP at Cytek Biosciences, reports the acquisition of stock options and restricted stock units.
NASDAQ
Valerie Barnett, Chief Legal Officer of Cytek Biosciences, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.